News & Events

News

All categories

Earnings

Press Release

All years

2020

2019

2018

2017

2016

2015

2014

Affimed ASCO Data Demonstrate Consistent Potency of NK- Cell-Engaging Combination Therapy with Checkpoint Modulators

May 29, 2015

Affimed ASCO Data for the CD33/CD3-TandAb Program Demonstrate that CD33 and CD3 binding affinities correlate with potent T-cell activation and cytotoxicity

May 29, 2015

Affimed to Present at the Jefferies 2015 Healthcare Conference – New York

May 27, 2015

Affimed Completes TandAb Development Candidate Activities Meeting Amphivena’s and Janssen’s Criteria and Achieves Milestone Ahead of Schedule

May 24, 2015

Affimed Reports Financial Results for First Quarter 2015

May 21, 2015

Affimed to Present Data at ASCO to Highlight Potency of NK- Cell-Engaging Combination Therapy with Checkpoint Modulators

May 13, 2015

Affimed Announces First Quarter 2015 Financial Results Conference Call

May 13, 2015

Affimed N.V. Announces Shareholder Meeting

May 12, 2015

Affimed N.V. Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares

May 12, 2015

Affimed to Present at the UBS Global Healthcare Conference – New York

May 12, 2015

Events

All

Scientific

Investors

24Mar

Innate Killer Summit 2020

March 24 - 26, 2020 (San Diego, USA)
Presenter: Joachim Koch

Webcasts
More events

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.